NASDAQ:SNCE Science 37 (SNCE) Stock Forecast, Price & News $0.40 +0.00 (+1.08%) (As of 02:44 PM ET) Add Compare Share Share Today's Range$0.39▼$0.4150-Day Range$0.22▼$0.5952-Week Range$0.19▼$1.99Volume142,116 shsAverage Volume939,253 shsMarket Capitalization$47.35 millionP/E RatioN/ADividend YieldN/APrice Target$2.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Science 37 MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside493.9% Upside$2.33 Price TargetShort InterestHealthy1.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector369th out of 963 stocksCommercial Physical Research Industry7th out of 14 stocks 3.4 Analyst's Opinion Consensus RatingScience 37 has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.33, Science 37 has a forecasted upside of 493.9% from its current price of $0.39.Amount of Analyst CoverageScience 37 has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.41% of the float of Science 37 has been sold short.Short Interest Ratio / Days to CoverScience 37 has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Science 37 has recently decreased by 5.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldScience 37 does not currently pay a dividend.Dividend GrowthScience 37 does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNCE. Previous Next 2.9 News and Social Media Coverage News SentimentScience 37 has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Science 37 this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for SNCE on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Science 37 to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Science 37 insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Science 37 is held by insiders.Percentage Held by Institutions40.67% of the stock of Science 37 is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Science 37 is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Science 37 is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScience 37 has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Science 37 (NASDAQ:SNCE) StockScience 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.Read More SNCE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNCE Stock News HeadlinesSeptember 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Science 37 (SNCE)September 20, 2023 | finance.yahoo.comScience 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 ListSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 18, 2023 | americanbankingnews.comScience 37 Holdings, Inc. (NASDAQ:SNCE) Short Interest UpdateSeptember 12, 2023 | finance.yahoo.comScience 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & SullivanSeptember 5, 2023 | finance.yahoo.comScience 37 to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | finance.yahoo.comScience 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA AwardsAugust 13, 2023 | barrons.comScience 37 Holdings Inc.September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 11, 2023 | finance.yahoo.comIncreasing losses over year doesn't faze Science 37 Holdings (NASDAQ:SNCE) investors as stock rallies 122% this past weekAugust 9, 2023 | investing.comScience 37 Holdings (SNCE) Earnings Dates & ReportsAugust 8, 2023 | finanznachrichten.deScience 37, Inc.: Science 37 Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comScience 37 GAAP EPS of -$0.17 misses by $0.02, revenue of $15.35M beats by $2.78MAugust 8, 2023 | finance.yahoo.comScience 37 Reports Second Quarter 2023 Financial ResultsAugust 7, 2023 | benzinga.comScience 37 Hldgs Earnings PreviewJuly 25, 2023 | finance.yahoo.comScience 37 to Report Second Quarter 2023 Financial Results on August 8, 2023July 11, 2023 | finance.yahoo.comSynlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)July 11, 2023 | finance.yahoo.comSynlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)July 8, 2023 | finanznachrichten.deScience 37, Inc.: Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)May 18, 2023 | finance.yahoo.comScience 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"May 15, 2023 | finanznachrichten.deScience 37, Inc.: Science 37 Reports First Quarter 2023 Financial ResultsMay 15, 2023 | finance.yahoo.comScience 37 Reports First Quarter 2023 Financial ResultsMay 14, 2023 | marketwatch.com8-K: Science 37 Holdings, Inc.May 2, 2023 | finance.yahoo.comScience 37 Joins Partnership in Support of White House CancerX and Cancer MoonshotMay 1, 2023 | finance.yahoo.comScience 37 to Report First Quarter 2023 Financial Results on May 15, 2023April 25, 2023 | finance.yahoo.comScience 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, DiversityApril 20, 2023 | finance.yahoo.comScience 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical ResearchSee More Headlines Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Email Address SNCE Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNCE CUSIPN/A CIK1819113 Webwww.lifesciacquisition.com Phone984-377-3737FaxN/AEmployees460Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.33 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+483.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,990,000.00 Net Margins-217.87% Pretax Margin-218.01% Return on Equity-77.11% Return on Assets-60.60% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.62 Sales & Book Value Annual Sales$70.15 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.48Miscellaneous Outstanding Shares117,110,000Free Float108,563,000Market Cap$46.84 million OptionableNot Optionable Beta1.27 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David Coman (Age 53)CEO & Director Comp: $796.13kMs. Christine A. Pellizzari J.D. (Age 55)Chief Legal & HR Officer and Sec. Comp: $521.58kMs. Darcy Forman (Age 47)Chief Delivery Officer Comp: $550.58kMr. Mike Zaranek (Age 52)Chief Financial Officer Troy BryentonChief Technology OfficerIrena LambridisVP and Head of Quality Assurance & ComplianceMs. Margie Gimbel KoomanVP of Marketing & CommunicationsMr. Drew BustosChief Strategy & Marketing OfficerMr. Jonathan Cotliar M.D. (Age 51)Chief Medical Officer Mr. Michael Shipton (Age 51)Chief Commercial Officer More ExecutivesKey CompetitorsInotivNASDAQ:NOTVAIkido PharmaNASDAQ:AIKIData Knights AcquisitionNASDAQ:DKDCAAbsciNASDAQ:ABSIFSD PharmaNASDAQ:HUGEView All CompetitorsInsiders & InstitutionsY Intercept Hong Kong LtdBought 343,348 shares on 8/15/2023Ownership: 0.293%Goldman Sachs Group Inc.Bought 127,338 shares on 8/15/2023Ownership: 0.281%State Street CorpSold 804,739 shares on 8/14/2023Ownership: 0.168%Renaissance Technologies LLCBought 263,213 shares on 8/11/2023Ownership: 0.551%Geode Capital Management LLCSold 530,763 shares on 8/11/2023Ownership: 0.516%View All Insider TransactionsView All Institutional Transactions SNCE Stock - Frequently Asked Questions Should I buy or sell Science 37 stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SNCE shares. View SNCE analyst ratings or view top-rated stocks. What is Science 37's stock price forecast for 2023? 4 analysts have issued 12-month price targets for Science 37's shares. Their SNCE share price forecasts range from $1.00 to $3.00. On average, they predict the company's stock price to reach $2.33 in the next year. This suggests a possible upside of 483.3% from the stock's current price. View analysts price targets for SNCE or view top-rated stocks among Wall Street analysts. How have SNCE shares performed in 2023? Science 37's stock was trading at $0.4152 at the beginning of the year. Since then, SNCE stock has decreased by 3.7% and is now trading at $0.40. View the best growth stocks for 2023 here. When is Science 37's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our SNCE earnings forecast. How were Science 37's earnings last quarter? Science 37 Holdings, Inc. (NASDAQ:SNCE) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.10) EPS for the quarter. The company had revenue of $15.35 million for the quarter, compared to analyst estimates of $11 million. Science 37 had a negative net margin of 217.87% and a negative trailing twelve-month return on equity of 77.11%. What guidance has Science 37 issued on next quarter's earnings? Science 37 issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60.00 million-$60.00 million, compared to the consensus revenue estimate of $56.94 million. What is Science 37's stock symbol? Science 37 trades on the NASDAQ under the ticker symbol "SNCE." Who are Science 37's major shareholders? Science 37's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.58%), Renaissance Technologies LLC (0.55%), Kingswood Wealth Advisors LLC (0.55%), Geode Capital Management LLC (0.52%), Y Intercept Hong Kong Ltd (0.29%) and Goldman Sachs Group Inc. (0.28%). View institutional ownership trends. How do I buy shares of Science 37? Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Science 37's stock price today? One share of SNCE stock can currently be purchased for approximately $0.40. How much money does Science 37 make? Science 37 (NASDAQ:SNCE) has a market capitalization of $46.84 million and generates $70.15 million in revenue each year. The company earns $-50,990,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. How many employees does Science 37 have? The company employs 460 workers across the globe. How can I contact Science 37? Science 37's mailing address is 250 W 55TH ST. #3401, NEW YORK NY, 10019. The official website for the company is www.lifesciacquisition.com. The company can be reached via phone at 984-377-3737 or via email at investment@lifesciacquisition.com. This page (NASDAQ:SNCE) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Science 37 Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.